lication No.	Applicant(s)		
07,201	SALCEDA ET AL.	ALCEDA ET AL.	
miner	Art Unit		
H-TAM DAVIS	1642		
REMAINS) CLOSED in the repropriate communication in the communication in the repropriate communication in the communication in the repropriet in the communication in the repropriet in the repropriet in the communication in the repropriet in the r	is application. If not included cation will be mailed in due cours		
		*	
received. received in Application I	No	rom the	
s communication to file a of this application.	reply complying with the requirer	ments	
		E OF	
endment / Comment or in	the Office action of drawings in the front (not the back	x) of	
		the	
	mal Patent Application (PTO-152	5 \	
	miner H-TAM DAVIS In the cover sheet with REMAINS) CLOSED in the appropriate communics. This application is subMPEP 1308. 5 U.S.C. § 119(a)-(d) or	Miner Art Unit H-TAM DAVIS 1642 In the cover sheet with the correspondence address-REMAINS) CLOSED in this application. If not included her appropriate communication will be mailed in due cours in this application is subject to withdrawal from issue at the MPEP 1308. 5 U.S.C. § 119(a)-(d) or (f). I received. I received in Application No Into have been received in this national stage application for this application. Note the attached EXAMINER'S AMENDMENT or NOTICE is con(s) why the oath or declaration is deficient.	

Application/Control Number: 09/807,201

Art Unit: 1642

EXAMINER'S AMENDMENT

It is noted that Applicant's response filed March 08, 2004 placed the application in condition for allowance based on the record at that time. The Examiner's Amendment is made in lieu of reopening prosecution in order to remedy informalities which were brought to Applicant's attention for the first time in the telephone Interview of March 09, 2004. Accordingly, no further extension of time is required to make the Examiner's Amendment which places the Application fully in condition for allowance.

1. The oath or declaration is defective because:

Non-initiated and/or non-dated alterations have been made to the oath or declaration. See 37 CFR 1.52(c).

A new oath or declaration in compliance with 37 CFR 1.67(a) identifying this application by application number and filing date is required. See MPEP § § 602.01 and 602.02

This application will not be passed to issue until a new declaration is submitted with (a) a statement acknowledging the duty to disclose material which occurred between the filing date of the prior application and the continuation-in part application, and (b) continuing data that matches the priority claimed in paragraph 1 of page 1 of the specification. See M.P.E.P. § 605.04.filed as provided by 37 C.F.R. § 1.312. To ensure consideration of such an amendment, it **MUST** be submitted no later than the payment of the Issue Fee.

2. An examiner's amendment to the record appears below. Should the changes and/or additions be unacceptable to applicant, an amendment may be filed as provided

Application/Control Number: 09/807,201

Art Unit: 1642

by 37 CFR 1.312. To ensure consideration of such an amendment, it MUST be submitted no later than the payment of the issue fee.

Authorization for this examiner's amendment was given in a telephone interview with Kathleen Tyrrell on 03/09/04.

The application has been amended as follows:

In the specification:

The following continuation data has been inserted on the first line of the specification:

This application is a 371 national stage application of PCT/US99/24331, filed 10/19/1999.

In the claims:

Claim 1 was amended as follows:

A method for diagnosing the presence of prostate cancer in a patient comprising:

- (a) determining the level of SEQ ID No: 7 or 8 in prostate cells, tissues or in blood, plasma, serum or urine from a patient; and
- b) comparing the determined level of SEQ ID NO: 7 or 8 with the level of SEQ ID NO: 7 or 8 in prostate cells, or tissues or blood, plasma, serum or urine from a normal human control, wherein an increase in the determined level of SEQ ID NO: 7 or 8 in said patient versus normal human control is associated with the presence of prostate cancer.

Claims 2-12 have been cancelled.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to MINH-TAM DAVIS whose telephone number is 571-272-0830. The examiner can normally be reached on 9:30AM-4:00PM.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, CHRISTINA CHAN can be reached on 571-272-0841. The fax phone number for the organization where this application or proceeding is assigned is 703-872-9306.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).

MINH TAM DAVIS May 08, 2004

SUSAN UNGAR, PHAD